ESR1 and breast cancer: However, it is increased expression of RUNX2 that is generally associated with breast cancer transcriptomic datasets in both ER positive and ER negative subtypes (Figure 1), and accordingly, RUNX2 has been shown to adopt a pro-oncogenic role in breast cancer cells.